These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 16950021)

  • 1. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
    Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
    Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
    J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
    Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
    J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
    Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus testing for primary screening of cervical cancer precursors.
    Ratnam S; Franco EL; Ferenczy A
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):945-51. PubMed ID: 11008913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
    Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
    Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods.
    Layfield LJ; Qureshi MN
    Diagn Cytopathol; 2005 Aug; 33(2):138-43. PubMed ID: 16007672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
    Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
    J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.
    Jones J; Powell NG; Tristram A; Fiander AN; Hibbitts S
    J Clin Virol; 2009 Jun; 45(2):100-4. PubMed ID: 19394266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chapter 10: New dimensions in cervical cancer screening.
    Cuzick J; Mayrand MH; Ronco G; Snijders P; Wardle J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/90-7. PubMed ID: 16950022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
    Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
    Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of the impact of adding HPV types to cervical cancer screening and triage tests.
    Schiffman M; Khan MJ; Solomon D; Herrero R; Wacholder S; Hildesheim A; Rodriguez AC; Bratti MC; Wheeler CM; Burk RD; ;
    J Natl Cancer Inst; 2005 Jan; 97(2):147-50. PubMed ID: 15657345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic human papillomavirus testing in an adolescent population with atypical squamous cells of undetermined significance.
    Fletcher AH; Wilkinson EJ; Knapik JA
    J Low Genit Tract Dis; 2009 Jan; 13(1):28-32. PubMed ID: 19098603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV testing: where are we now?
    Bovicelli A; Bristow RE; Montz FJ
    Anticancer Res; 2000; 20(6C):4673-80. PubMed ID: 11205199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment.
    Ronco G; Brezzi S; Carozzi F; Dalla Palma P; Giorgi-Rossi P; Minucci D; Naldoni C; Segnan N; Zappa M; Zorzi M; Cuzick J;
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S230-2. PubMed ID: 17822751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.